Mangrove Partners’s iShares Biotechnology ETF IBB Stock Holding History

Mangrove Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-134,281	Closed	-$17M	–	170
2023 Q2	$17M	Buy	+134,281	New	+$17.4M	1.18%	28

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mangrove Partners's IBB Position: Q3 2023 in Review

Mangrove Partners sold out of iShares Biotechnology ETF (IBB) in Q3 2023, closing a stake of 134,281 shares — an estimated $17M sold.

Mangrove Partners first reported a position in IBB in Q2 2023 and held it in 1 quarter. The position peaked at $17M in Q2 2023. 832 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Mangrove Partners reported no remaining iShares Biotechnology ETF position as of Q3 2023 after selling out during the quarter.
Mangrove Partners sold 134,281 iShares Biotechnology ETF shares in Q3 2023, an estimated $17M.
Mangrove Partners first reported a position in iShares Biotechnology ETF in Q2 2023 and held it in 1 quarter.
Mangrove Partners's iShares Biotechnology ETF position peaked at $17M in Q2 2023.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Mangrove Partners's 13F filing for Q3 2023, filed 14 Nov 2023.